04 July 2017

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that the Company is today presenting to institutional investors on its topical gel for erectile dysfunction, MED2002.

MED2002 represents a breakthrough treatment for erectile dysfunction ("ED") with the potential to offer the fastest speed of onset, the least side-effects and the fewest contra-indications of any ED medication.

Today's presentation is based on the presentation that Futura gives to potential licensing partners and comprises a detailed insight into key aspects of the clinical development and commercial potential of the product.

The presentation is taking place at noon today at the Surrey Research Park, where Futura is based, as part of a capital markets event organised by N+1 Singer, the Company's nominated adviser and broker.

A copy of the slide deck accompanying the presentation is now available at the investor section of Futura's website, www.futuramedical.com.

No new price sensitive information will be disclosed.


For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
+44 (0) 1483 685 670

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Mark Court / Sophie Wills /
Stephanie Watson / Tilly Abraham
Tel: +44 (0) 20 7466 5000


Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.